Biotech RadarJobs updated

COMPANY

Arcutis Biotherapeutics

HQ: Westlake Village, CA source · arcutis.com ↗

FDA-approved therapeutic company Clinical Phase 3

8 open jobs · last seen Oct 23, 2026 · 27 sources

Location: Westlake Village, CA · source · Oct 12, 2026

Profile checked Oct 10, 2026

Keywords: Chronic Plaque Psoriasis Psoriasis Plaque Psoriasis Atopic Dermatitis Eczema Seborrheic Dermatitis Atopic Dermatitis (Eczema) Atopic Dermatitis Eczema Scalp Psoriasis Vitiligo Chronic Hand Eczema ARQ-151 ARQ-252 ARQ-234 ARQ-154 Roflumilast

8Open jobs25Trials (company is sponsor)3FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Primary Care High Value SpecialistUSOct 23, 2026Oct 23, 2026
Therapeutic Sales Specialist - Worcester, MAUSOct 21, 2026Oct 21, 2026
Overlay Therapeutic Sales Specialist - Long Island, NYUSOct 9, 2026Oct 11, 2026
Regional Sales Director - South FloridaUSOct 6, 2026Oct 11, 2026
Overlay Therapeutic Sales Specialist - Atlanta, GAUSSep 26, 2026Oct 11, 2026

See all 8 jobs

Timeline

  1. FDA FDA New indication / efficacy supplement: ZORYVE (roflumilast) — NDA215985/15, Jun 29, 2026. Applicant at approval: Arcutis Biotherapeutics, Inc. source ↗
  2. Trial start Phase 1: Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 source ↗
  3. Trial start Phase 1: Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis source ↗
  4. FDA FDA New indication / efficacy supplement: ZORYVE (roflumilast) — NDA215985/12, Oct 4, 2025. Applicant at approval: Arcutis Biotherapeutics, Inc. source ↗
  5. Trial start Phase 2: Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis source ↗
  6. FDA FDA New indication / efficacy supplement: ZORYVE (roflumilast) — NDA217242/5, May 22, 2025. Applicant at approval: Arcutis Biotherapeutics, Inc. source ↗
  7. Trial start Phase 3: Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) source ↗
  8. Trial start Phase 3: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) source ↗
  9. Trial start Phase 3: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) source ↗
  10. Trial start Phase 2: Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo source ↗
  11. Trial start Phase 2: Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) source ↗
  12. Trial start Phase 3: Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis source ↗
  13. Trial start Phase 3: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) source ↗
  14. Trial start Phase 3: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis source ↗
  15. Trial start Phase 2: Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) source ↗
  16. Trial start Phase 2: Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis source ↗
  17. Trial start Phase 1/Phase 2: Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema source ↗
  18. Trial start Phase 1: Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis source ↗
  19. Trial start Phase 3: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis source ↗
  20. Trial start Phase 2: Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis source ↗
  21. Trial start Phase 1: Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema source ↗
  22. Trial start Phase 3: Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis source ↗
  23. Trial start Phase 3: Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis source ↗
  24. Trial start Phase 2: Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis source ↗
  25. Trial start Phase 2: Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis source ↗

Showing 25 of 28 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 25

RecordTitlePhaseStatusStartPrimary completion
NCT07453602Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234Phase 1RecruitingMar 2, 20262028-04 (estimated)
NCT04286607Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPhase 3CompletedFeb 12, 2020Jan 22, 2024 (actual)
NCT04746911Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Phase 2CompletedMar 1, 2021May 11, 2022 (actual)
NCT07340216Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisPhase 1CompletedDec 15, 2025Apr 30, 2026 (actual)
NCT04804605Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisPhase 3CompletedFeb 25, 2021May 28, 2024 (actual)
NCT04845620Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)Phase 3CompletedApr 7, 2021Jun 1, 2023 (actual)
NCT06998056Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisPhase 2CompletedJun 9, 2025Dec 4, 2025 (actual)
NCT05028582Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)Phase 3CompletedAug 24, 2021Jun 3, 2022 (actual)
NCT04773587Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisPhase 3CompletedJan 27, 2021Aug 30, 2022 (actual)
NCT04773600Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)Phase 3CompletedFeb 24, 2021Sep 29, 2022 (actual)
NCT04811131Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoPhase 2TerminatedMar 4, 2021Aug 9, 2021 (actual)
NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisPhase 2CompletedJun 12, 2020Nov 19, 2022 (actual)
NCT04378569Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand EczemaPhase 1/Phase 2CompletedApr 20, 2020Feb 24, 2021 (actual)
NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)Phase 3CompletedJul 8, 2021Apr 6, 2022 (actual)
NCT04655313Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)Phase 2CompletedNov 30, 2020Jan 12, 2022 (actual)
NCT04156191Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate EczemaPhase 1CompletedDec 23, 2019May 2, 2023 (actual)
NCT04091646Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisPhase 2CompletedDec 4, 2019Aug 18, 2020 (actual)
NCT03916081Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic DermatitisPhase 2CompletedMay 31, 2019Nov 4, 2019 (actual)
NCT04211363Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPhase 3CompletedDec 20, 2019Nov 16, 2020 (actual)
NCT04211389Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPhase 3CompletedDec 17, 2019Nov 23, 2020 (actual)
NCT04128007Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body PsoriasisPhase 2CompletedJan 13, 2020Sep 23, 2020 (actual)
NCT03764475Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque PsoriasisPhase 2CompletedDec 18, 2018Oct 8, 2020 (actual)
NCT03638258The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisPhase 2CompletedSep 21, 2018May 29, 2019 (actual)
NCT03392168Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque PsoriasisPhase 1/Phase 2CompletedDec 11, 2017May 2, 2018 (actual)
NCT04279119Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque PsoriasisPhase 1CompletedMar 10, 2020Mar 25, 2021 (actual)

FDA records (last 2 years)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 8

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Primary Care High Value SpecialistUSOct 23, 2026Oct 23, 2026Not stated
Therapeutic Sales Specialist - Worcester, MAUSOct 21, 2026Oct 21, 2026Not stated
Overlay Therapeutic Sales Specialist - Long Island, NYUSOct 9, 2026Oct 11, 2026Mid
Regional Sales Director - South FloridaUSOct 6, 2026Oct 11, 2026Senior
Overlay Therapeutic Sales Specialist - Atlanta, GAUSSep 26, 2026Oct 11, 2026Mid
Therapeutic Sales Specialist - Brooklyn, NYUSSep 18, 2026Oct 11, 2026Mid
Director HCP MarketingUSSep 4, 2026Oct 11, 2026Senior
Therapeutic Sales Specialist - Arlington, VAUSAug 6, 2026Oct 22, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Arcutis Biotherapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback